JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

AbbVie Inc

Chiusa

SettoreSettore sanitario

206.03 -1.03

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

205.81

Massimo

208.41

Metriche Chiave

By Trading Economics

Entrata

1.6B

1.8B

Vendite

-1.6B

15B

P/E

Media del settore

101.049

49.8

EPS

2.65

Rendimento da dividendi

3.26

Margine di Profitto

10.928

Dipendenti

57,000

EBITDA

-635M

4.7B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+22.3% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.26%

2.25%

Utili prossimi

30 lug 2026

Prossima data del Dividendo

15 mag 2026

Prossima data del' Ex Dividendo

14 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

19B

368B

Apertura precedente

207.06

Chiusura precedente

206.03

Notizie sul Sentiment di mercato

By Acuity

16%

84%

31 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

AbbVie Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 12:38 UTC

Utili

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 feb 2026, 13:20 UTC

Utili

AbbVie 4Q Revenue Rises on Immunology Growth

29 apr 2026, 12:41 UTC

Utili

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 apr 2026, 12:23 UTC

Utili

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 apr 2026, 11:50 UTC

Utili

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 apr 2026, 11:49 UTC

Utili

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 apr 2026, 11:48 UTC

Utili

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q EPS 39c >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q Net $695M >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q Rev $15B >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q Adj EPS $2.65 >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 apr 2026, 11:47 UTC

Utili

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 feb 2026, 19:38 UTC

Utili

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 16:19 UTC

Utili

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 15:18 UTC

Utili

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 13:18 UTC

Utili

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q Rev $16.62B >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q Net $1.82B >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q Adj EPS $2.71 >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 feb 2026, 12:48 UTC

Utili

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Confronto tra pari

Modifica del prezzo

AbbVie Inc Previsione

Obiettivo di Prezzo

By TipRanks

22.3% in crescita

Previsioni per 12 mesi

Media 252.68 USD  22.3%

Alto 294 USD

Basso 203 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbbVie Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

21 ratings

15

Acquista

6

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

180.37 / 195.54Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

31 / 347 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
help-icon Live chat